IL1F10 and neoplasm: This aligns with other studies showing that anti-IL-38 antibody treatment, targeting both human and mouse IL-38 proteins, also exhibits a tumour-inhibitory role in animals receiving epithelial-mesenchymal transition cancer cells (44).